Patents by Inventor Martin Hofmann

Martin Hofmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11905328
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 20, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Martin Hofmann, Felix Unverdorben, Sebastian Bunk, Dominik Maurer
  • Publication number: 20240052054
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 15, 2024
    Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
  • Patent number: 11859009
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: January 2, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Gabriele Pszolla, Martin Hofmann, Meike Hutt, Sebastian Bunk, Felix Unverdorben, Frank Schwoebel, Dominik Maurer, Maike Jaworski, Claudia Wagner, Florian Schwoerer, Heiko Schuster
  • Patent number: 11840577
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 12, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Meike Hutt, Felix Unverdorben, Sebastian Bunk, Dominik Maurer, Martin Hofmann, Gabriele Pszolla, Sara Yousef, Claudia Wagner, Frank Schwoebel, Heiko Schuster
  • Publication number: 20230357428
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: April 17, 2023
    Publication date: November 9, 2023
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • Publication number: 20230348598
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: June 8, 2023
    Publication date: November 2, 2023
    Inventors: Martin HOFMANN, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER
  • Patent number: 11801820
    Abstract: An electrically actuatable operating unit (106) for a motor vehicle brake comprises a housing body (122) which is arranged so as to be displaceable in a braking direction for operation of the motor vehicle brake, a recess (150) formed in the housing body (122), wherein the recess (150) is delimited at one longitudinal end by a contact shoulder (172), a through-opening (158) delimited by the contact shoulder (172), an operating member (124) which is arranged in the recess (150) so as to be displaceable for operation of the motor vehicle brake and projects through the through-opening (158) of the contact shoulder (172), wherein the operating member (124) can be arranged in a force-transmitting manner between a brake pedal and the motor vehicle brake (400).
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 31, 2023
    Assignee: ZF Active Safety GmbH
    Inventors: Kurt Wingender, Martin Hofmann, José Manuel Calvo Martinez, Martin Sakalla, Iosu Oloriz del Rosario, Jennifer Klein
  • Publication number: 20230320826
    Abstract: A tool tip (10) for a tool being intended for a dental treatment, in particular for a piezoelectric scaler, comprising—a first section (11) extending in a first direction (D1) and—a second section (12) extending in a second direction (D2), the second direction (D2) being inclined relative to the first direction (D1), wherein the first section (11) has at least partially a flat basic body (5).
    Type: Application
    Filed: September 16, 2021
    Publication date: October 12, 2023
    Inventors: Martin HOFMANN, Jürgen BURGER, Thomas NIEDERHAUSER, Dominik WENGER, Diego STUTZER, Sigrun EICK, Alex BIENAIMÉ, Maxime FOURNIER
  • Publication number: 20230243433
    Abstract: A directional control valve for handling fluids, such as cooling and/or heating fluids, may be used in a motor vehicle, such as an electrically operated motor vehicle. The directional control value may include: a valve housing defining at least one fluid channel including at least one fluid inlet and at least one fluid outlet, and at least one fluid connecting piece adapted to the at least one fluid inlet or fluid outlet. The fluid connecting piece may be positively connected to the valve housing using a bayonet mechanism. The directional control may include a multi-way valve.
    Type: Application
    Filed: June 10, 2021
    Publication date: August 3, 2023
    Applicant: WOCO Industrietechnik GmbH
    Inventors: Eberhard Geissel, Torsten Hofmann, Martin Hofmann, Michael Kolb, Rita Spomer
  • Publication number: 20230203200
    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.
    Type: Application
    Filed: November 2, 2022
    Publication date: June 29, 2023
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
  • Patent number: 11680929
    Abstract: An apparatus for collecting liquid fractions from a separation/reaction apparatus (1). A capillary (2) guides an extracted liquid fraction to a branching unit (3), a collection arrangement (4) carries a plurality of target vessels (5) receiving the liquid fraction from the capillary and a fluid line (6) is flow-connected to a fluid pump (7) and opens into the branching unit. The capillary and the fluid line each have outlet openings in the direct vicinity of one another at their end facing a target vessel such that liquid emerging from the outlet opening (2?) of the capillary transitions into the outlet opening (6?) of the fluid line. This precludes back mixing with earlier/later liquid fractions, precludes uncontrolled dripping of sample substance at the transfer point, speeds displacement of the target vessels in the collection arrangement, facilitates automation of the fraction processing procedure, and results in a more compact fraction collection apparatus.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: June 20, 2023
    Assignee: Bruker BioSpin GmbH
    Inventors: Ernst Ulrich Braumann, Martin Hofmann
  • Publication number: 20230172252
    Abstract: The current invention relates to a method for producing emulsions using a layer multiplayer comprising the steps of: providing at least two immiscible fluid streams, combining said immiscible fluid streams to a focused total fluid stream, and subsequently carrying out baker's transformations on said total fluid stream, said baker's transformation comprises: (i) stretching and cutting said total fluid stream; (ii) recombining said total fluid stream. The present invention further relates to the use of said method for food grade, polymer, cosmetic and pharmaceutical products. The present invention further relates to said food grade, polymer, cosmetic and pharmaceutical products.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 8, 2023
    Inventors: Alexandra Victoria BAYLES, Martin HOFMANN, Jan VERMANT
  • Publication number: 20230148240
    Abstract: A write head for producing an object by way of two-photon polymerization, comprising: a monolithic mode-locked laser diode, a microscope objective that is configured and arranged to focus laser radiation generated by the monolithic mode-locked laser diode.
    Type: Application
    Filed: June 2, 2021
    Publication date: May 11, 2023
    Inventors: Nils Dominik Surkamp, Gordon Zyla, Martin Hofmann, Cemal Esen, Evgeny Gurevich
  • Publication number: 20230132241
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 27, 2023
    Inventors: Sebastian BUNK, Martin HOFMANN, Meike HUTT, Dominik MAURER, Gabriele PSZOLLA, Frank SCHWOEBEL, Felix UNVERDORBEN, Claudia WAGNER, Sara YOUSEF
  • Publication number: 20230091330
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 23, 2023
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • Patent number: 11536830
    Abstract: A vehicle radar system (3) which, for each one of a plurality of radar cycles, is arranged to, provide a measured azimuth angle (?m) and radial velocity (vdm) for a first plurality of detections (9, 20). For each one of the plurality of radar cycles, the radar system (3) is arranged to select one of these detections for each one of two velocity components (vx, vy) in a set of components (vx, vy, ax, ay; a) to be determined; select one detection from a second plurality of detections (9, 20) for each one of at least one corresponding acceleration component (ax, ay; a); calculate the components (vx, vy, ax, ay; a) for the selected detections; determine a calculated radial velocity (vdc) for each one of at least a part of the other detections in the first plurality of detections (9, 20) using the calculated components (vx, vy, ax, ay; a); determine an error between each calculated and measured radial velocity (vdc, vdm); and determine the number of inliers.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: December 27, 2022
    Assignee: Arriver Software AB
    Inventors: Martin Hofmann, Habib Ur Rehman Paracha
  • Publication number: 20220372165
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • Publication number: 20220356252
    Abstract: Antigen binding polypeptide specifically binding to ?/? T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector, and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the ?/? TCR/CD3 complex.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 10, 2022
    Inventors: Sebastian BUNK, Felix UNVERDORBEN, Martin HOFMANN
  • Publication number: 20220278511
    Abstract: A tool system for mounting an elastic sleeve includes a holdout tube supporting the elastic sleeve prior to and during mounting, the holdout tube having a longitudinal axis, an interface element movable along the longitudinal axis and transferring pressure onto the elastic sleeve to push the elastic sleeve off the holdout tube during mounting, and an actuation lever engaging the holdout tube at a fulcrum region of the actuation lever. The actuation lever has a pair of load arms partly encompassing the holdout tube. A load region is arranged at a peripheral end of each of the load arms. The actuation lever actuates the interface element by pressing the load regions of the actuation lever against the interface element.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 1, 2022
    Applicant: Tyco Electronics Raychem GmbH
    Inventors: Thilo Simonsohn, Christian Heindl, Martin Hofmann
  • Publication number: 20220195044
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: March 12, 2022
    Publication date: June 23, 2022
    Inventors: Martin HOFMANN, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER